The minimal set of genetic alterations required for conversion of primary human fibroblasts to cancer cells in the subrenal capsule assay

Neoplasia

Volumn 7, Issue 6, 2005, Pages 585-593

  Sun, Beicheng ^a   Chen, Meizhen ^a   Hawks, Christina L ^a   Pereira Smith, Olivia M ^a,b   Hornsby, Peter J ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Crisis; Human fibroblasts; Immunodeficient mice; Replicative senescence; Telomeres

Indexed keywords

PHOSPHATASE; PHOSPHATASE 2A; RAS PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; VIRUS LARGE T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENICITY; CELL GROWTH; CELL POPULATION; CELL TRANSFORMATION; CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG SCREENING; ENZYME ACTIVITY; FIBROBLAST; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; KIDNEY CAPSULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TELOMERE;

EID: 22044452711     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.05172     Document Type: Article

References (43)

1. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, and Weinberg RA (1999). Creation of human tumour cells with defined genetic elements. Nature 400, 464-468.
2. Hahn WC and Weinberg RA (2002). Modelling the molecular circuitry of cancer. Nat Rev Cancer 2, 331-341.
3. Zhao JJ, Roberts TM, and Hahn WC (2004). Functional genetics and experimental models of human cancer. Trends Mol Med 10, 344-350.
4. Bogden AE, Kelton DE, Cobb WR, and Esber HJ (1978). A rapid screening method for testing for testing chemotherapeutic agents against human tumor xenografts. In Houchens DP, Ovejera AA (Eds.), Proceedings of the Symposium on the Use of Athymic (Nude) Mice in Cancer Research, pp. 231-250. Gustav Fischer, New York.
5. Fingert HJ, Chen Z, Mizrahi N, Gajewski WH, Bamberg MP, and Kradin RL (1987). Rapid growth of human cancer cells in a mouse model with fibrin clot subrenal capsule assay. Cancer Res 47, 3824-3829.
6. Hayward SW, Haughney PC, Rosen MA, Greulich KM, Weier HU, Dahiya R, and Cunha GR (1998). Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. Differentiation 63, 131-140.
7. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, and Cunha GR (1999). Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59, 5002-5011.
8. Salup RR, Herberman RB, and Wiltrout RH (1985). Role of natural killer activity in development of spontaneous metastases in murine renal cancer. J Urol 134, 1236-1241.
9. Naito S, von Eschenbach AC, Giavazzi R, and Fidler IJ (1986). Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 46, 4109-4115.
10. Thomas M, Northrup SR, and Hornsby PJ (1997). Adrenocortical tissue formed by transplantation of normal clones of bovine adrenocortical cells in scid mice replaces the essential functions of the animals' adrenal glands. Nat Med 3, 978-983.
11. Thomas M, Yang L, and Hornsby PJ (2000). Formation of functional tissue from transplanted adrenocortical cells expressing telomerase reverse transcriptase. Nat Biotechnol 18, 39-42.
12. Thomas M, Wang X, and Hornsby PJ (2002). Human adrenocortical cell xenotransplantation: model of cotransplantation of human adrenocortical cells and 3T3 cells in scid mice to form vascularized functional tissue and prevent adrenal insufficiency. Xenotransplantation 9, 58-67.
13. Sun B, Huang Q, Liu S, Chen M, Hawks CL, Wang L, Zhang C, and Hornsby PJ (2004). Progressive loss of malignant behavior in telomerase-negative tumorigenic adrenocortical cells and restoration of tumorigenicity by human telomerase reverse transcriptase. Cancer Res 64, 6144-6151.
14. Chang S and DePinho RA (2002). Telomerase extracurricular activities. Proc Natl Acad Sci USA 99, 12520-12522.
15. O'Brien W, Stenman G, and Sager R (1986). Suppression of tumor growth by senescence in virally transformed human fibroblasts. Proc Natl Acad Sci USA 83, 8659-8663.
16. Seger YR, Garcia-Cao M, Piccinin S, Cunsolo CL, Doglioni C, Blasco MA, Hannon GJ, and Maestro R (2002). Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2, 401-413.
17. Miller AD and Rosman GJ (1989). Improved retroviral vectors for gene transfer and expression. Biotechniques 7, 980-982.
18. Pear WS, Nolan GP, Scott ML, and Baltimore D (1993). Production of high-liter helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90, 8392-8396.
19. Kriegler M (1990). Gene Transfer and Expression: A Laboratory Manual. Stockton Press, New York.
20. Sato Y, Mukai K, Furuya S, Kameya T, and Hirohashi S (1992). The AMeX method: a multipurpose tissue-processing and paraffin-embedding method. Extraction of protein and application to immunoblotting. Am J Pathol 140, 775-779.
21. Benanti JA and Galloway DA (2004). Normal human fibroblasts are resistant to RAS-induced senescence. Mol Cell Biol 24, 2842-2852.
22. Schultz LB, Chehab NH, Malikzay A, and Halazonetis TD (2000). p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol 151, 1381-1390.
23. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, and Jackson SP (2003). A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198.
24. Herbig U, Jobling WA, Chen BP, Chen DJ, and Sedivy JM (2004). Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 14, 501-513.
25. Wright WE and Shay JW (2002). Historical claims and current interpretations of replicative aging. Nat Biotechnol 20, 682-688.
26. Campisi J (2003). Cancer and ageing: rival demons? Nat Rev Cancer 3, 339-349.
27. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, DeCaprio JA, and Weinberg RA (2002). Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 22, 2111-2123.
28. Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT, Der CJ, and Counter CM (2002). Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 16, 2045-2057.
29. Hamad NM, Banik SS, and Counter CM (2002). Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells. Oncogens 21, 7121-7125.
30. Akagi T, Sasai K, and Hanafusa H (2003). Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation. Proc Natl Acad Sci USA 100, 13567-13572.
31. Voorhoeve PM and Agami R (2003). The tumor-suppressive functions of the human INK4A locus. Cancer Cell 4, 311-319.
32. Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC, and Hahn WC (2004). Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 5, 127-136.
33. Deng Q, Liao R, Wu BL, and Sun P (2004). High intensity ras signaling induces premature senescence by activating p38 pathway in primary human fibroblasts. J Biol Chem 279, 1050-1059.
34. Serrano M, Lin AW, Mccurrach ME, Beach D, and Lowe SW (1997). Oncogenic Ras provokes premature cell senescence associated with accumulation of p53 and p16 INK4A. Cell 88, 593-602.
35. Brookes S, Rowe J, Ruas M, Llanos S, Clark PA, Lomax M, James MC, Vatcheva R, Bates S, Vousden KH, et al. (2002). INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J 21, 2936-2945.
36. Huot TJ, Rowe J, Harland M, Drayton S, Brookes S, Gooptu C, Purkis P, Fried M, Bataille V, Hara E, et al. (2002). Biallelic mutations in p16 (INK4a) confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts. Mol Cell Biol 22, 8135-8143.
37. Drayton S, Rowe J, Jones R, Vatcheva R, Cuthbert-Heavens D, Marshall J, Fried M, and Peters G (2003). Tumor suppressor p16INK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes. Cancer Cell 4, 301-310.
38. Wei W, Jobling WA, Chen W, Hahn WC, and Sedivy JM (2003). Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits flas-induced anchorage-independent growth in telomerase-immortalized human fibroblasts. Mol Cell Biol 23, 2859-2870.
39. Wright WE and Shay JW (2001). Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr Opin Genet Dev 11, 98-103.
40. Ott CE and Knox FG (1976). Tissue pressures and fluid dynamics in the kidney. Fed Proc 35, 1872-1875.
41. Rich JN, Quo C, McLendon RE, Bigner DD, Wang XF, and Counter CM (2001). A genetically tractable model of human glioma formation. Cancer Res 61, 3556-3560.
42. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, and Weinberg RA (2001). Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 15, 50-65.
43. Lundberg AS, Randell SH, Stewart SA, Elenbaas B, Hartwell KA, Brooks MW, Fleming MD, Olsen JC, Miller SW, Weinberg RA, et al. (2002). Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 21, 4577-4586.